VEGFA and diabetes mellitus: Combined inhibition of VEGF and Ang2, as seen with faricimab, normalizes tumor vessels, reduces vascular permeability, and improves outcomes in diseases such as diabetic macular edema (DME, a complication of diabetes characterized by the accumulation of fluid in the macula due to damaged blood vessels) and AMD.200–202 This Ang-TIE-VEGF interplay is critical for vascular stability, and its imbalance contributes to diseases such as cancer.